Suppr超能文献

格雷夫斯病相关胆汁淤积的临床特征。

Clinical characteristics of Graves disease associated cholestasis.

机构信息

Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jan 28;46(1):47-52. doi: 10.11817/j.issn.1672-7347.2021.200004.

Abstract

OBJECTIVES

A variety of causes can lead to cholestasis, however, cholestasis caused by Graves' disease is usually overlooked clinically. Here we analyze the clinical characteristics of Graves' disease associated cholestasis so as to have a better understanding for the disease.

METHODS

We retrospectively collected 13 inpatients' data who suffered from the Graves' disease associated cholestasis in the Department of Infectious Disease of Xiangya Hospital from January 2000 to December 2018. The characteristics of the patients' age, gender, liver function, thyroid function, coagulation function, the special cardiac examination, treatment, and follow-up data were analyzed.

RESULTS

Thirteen patients, including 10 males and 3 females with the age range from 33 to 55 (median 43) years old presented cholestasis, pruritus, and hypermetabolic symptoms. The levels of total bilirubin (TBIL), direct bilirubin (DBIL), glutamic-pyruvic transferase, glutamic-oxaloacetic transferase, alkaline phosphosphatase, and gamma glutamyl transpeptidase were 170.4-976.7 (median 388.8) µmol/L, 93.2-418.1 (median 199.2) µmol/L, 25.1-182.1 (median 106.4) U/L, 38.2-265.7 (median 59.7) U/L, 105.3-332.0 (median 184.5) U/L, and 20.7-345.1 (median 47.6) U/L, respectively. The levels of free triiodothyronine (FT), free thyroxine (FT), and thyrotrophin receptor antibody were 4.1-50.0 (median 21.6) pmol/L, 30.4-100.0 (median 87.9) pmol/L, and 4.2-40 (median 19.8) U/mL, respectively. All patients' coagulation function, heart size, and ejection fraction (EF) value were normal. After anti-thyroid treatment, the levels of FT, FT, and TBIL decreased. Through telephone interview, we were able to know that after 6 months of anti-thyroid treatment, the level of FT, FT, and TBIL in these patients returned to normal, and the itch symptom disappeared completely.

CONCLUSIONS

Graves' disease can cause cholestasis, with the low incidence. The symptoms of cholestasis can be improved or even eradicated with the cure of the Graves' disease. The cholestasis may be idiopathic. For patients with cholestasis and hyperthyroidism, Graves' disease should be considered for differential diagnosis.

摘要

目的

多种原因可导致胆汁淤积,但临床上常忽略由 Graves 病引起的胆汁淤积。本研究旨在分析 Graves 病相关胆汁淤积的临床特征,以加深对该病的认识。

方法

回顾性收集 2000 年 1 月至 2018 年 12 月在湘雅医院感染科住院的 13 例 Graves 病相关胆汁淤积患者的临床资料,分析其年龄、性别、肝功能、甲状腺功能、凝血功能、特殊心脏检查、治疗及随访资料等特点。

结果

13 例患者中,男 10 例,女 3 例,年龄 3355 岁,中位年龄 43 岁,均有胆汁淤积、瘙痒和高代谢症状。总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(γ-GT)水平分别为 170.4976.7(中位 388.8)μmol/L、93.2418.1(中位 199.2)μmol/L、25.1182.1(中位 106.4)U/L、38.2265.7(中位 59.7)U/L、105.3332.0(中位 184.5)U/L 和 20.7345.1(中位 47.6)U/L,游离三碘甲状腺原氨酸(FT₃)、游离甲状腺素(FT₄)、促甲状腺素受体抗体(TRAb)水平分别为 4.150.0(中位 21.6)pmol/L、30.4100.0(中位 87.9)pmol/L 和 4.240(中位 19.8)U/ml。所有患者凝血功能、心脏大小、射血分数(EF)值均正常。经抗甲状腺治疗后,FT₃、FT₄、TBIL 水平降低。通过电话随访,我们了解到这些患者在抗甲状腺治疗 6 个月后,FT₃、FT₄、TBIL 水平恢复正常,瘙痒症状完全消失。

结论

Graves 病可引起胆汁淤积,发病率较低。Graves 病治愈后,胆汁淤积的症状可改善甚至消除。胆汁淤积可能是特发性的。对于有胆汁淤积和甲状腺功能亢进的患者,应考虑 Graves 病的鉴别诊断。

相似文献

1
Clinical characteristics of Graves disease associated cholestasis.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jan 28;46(1):47-52. doi: 10.11817/j.issn.1672-7347.2021.200004.
2
Significant cardiac disease complicating Graves' disease in previously healthy young adults.
Endocrinol Diabetes Metab Case Rep. 2020 Jan 22;2020. doi: 10.1530/EDM-19-0132.
4
Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis.
Clin Endocrinol (Oxf). 2002 Jul;57(1):51-8. doi: 10.1046/j.1365-2265.2002.01558.x.
6
Clinical manifestations and early effectiveness of methimazole in patients with graves' hyperthyroidism-related severe hepatic dysfunction.
Scand J Gastroenterol. 2023 Jul-Dec;58(12):1514-1522. doi: 10.1080/00365521.2023.2244107. Epub 2023 Aug 7.
7
Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
Front Endocrinol (Lausanne). 2020 May 12;11:286. doi: 10.3389/fendo.2020.00286. eCollection 2020.
8
Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine.
Ann Med Surg (Lond). 2016 Aug 8;10:69-72. doi: 10.1016/j.amsu.2016.07.024. eCollection 2016 Sep.

引用本文的文献

1
Serum Levels of CXCL-13, RBP-4, and IL-6, and Correlation Analysis of Patients with Graves' Disease.
Emerg Med Int. 2022 Aug 12;2022:5131846. doi: 10.1155/2022/5131846. eCollection 2022.

本文引用的文献

1
Lift Then Shift: Thyrotoxic Periodic Paralysis.
Am J Med. 2019 Jan;132(1):e3-e6. doi: 10.1016/j.amjmed.2018.08.015. Epub 2018 Sep 7.
2
Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems.
Food Chem Toxicol. 2018 Oct;120:196-212. doi: 10.1016/j.fct.2018.07.017. Epub 2018 Jul 7.
3
CSH guidelines for the diagnosis and treatment of drug-induced liver injury.
Hepatol Int. 2017 May;11(3):221-241. doi: 10.1007/s12072-017-9793-2. Epub 2017 Apr 12.
4
Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature.
Medicine (Baltimore). 2017 Jan;96(4):e6017. doi: 10.1097/MD.0000000000006017.
6
Hyperthyroidism.
Lancet. 2016 Aug 27;388(10047):906-918. doi: 10.1016/S0140-6736(16)00278-6. Epub 2016 Mar 30.
7
Pruritus in cholestasis: facts and fiction.
Hepatology. 2014 Jul;60(1):399-407. doi: 10.1002/hep.26909. Epub 2014 May 29.
8
Hepatic dysfunction in hyperthyroidism.
Gastroenterol Hepatol (N Y). 2011 May;7(5):337-9.
10
Practical guidelines for diagnosis and early management of drug-induced liver injury.
World J Gastroenterol. 2008 Nov 28;14(44):6774-85. doi: 10.3748/wjg.14.6774.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验